BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  Who Should Get Credit for Saving the World from COVID-19?

  Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.

  March 22, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Fred Hutch Spinout Affini-T Tackles Cancer T-Cell Therapy with a Cool $175M

  Affini-T Therapeutics, a spin-out of the Fred Hutchinson Cancer Research Center, raised $175 million in initial financing. The company is focused on using T cells against mutations that drive cancer.

  March 22, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  AnaptysBio CEO Exits After Decade in the Role

  In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.

  March 22, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Merck’s Keytruda Adds Advanced Endometrial Carcinoma to Winning Roster

  Merck’s Keytruda has become an approved treatment for yet another indication: unresectable or metastatic advanced endometrial carcinoma. Know more about it here.

  March 22, 2022

   · 

  3 min read

   · 

  Jazmine Colatriano
• 

  Drug Development

  Studies Suggest Links Between COVID-19 and Diabetes, Pregnancy Risks and Dementia

  Study after study shows the disease comes with an increased risk of a number of health problems, including diabetes. One of the best ways to avoid those risks is to get vaccinated.

  March 22, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Aligos Takes Another Hit with Halt of Chronic Hepatitis B Therapy

  Aligos Therapeutics, headquartered in South San Francisco, halted the development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB).

  March 22, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Biomarkers: a Beacon of Hope for the Future of Alzheimer’s

  Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year’s International Conference on Alzheimer’s and Parkinson’s Diseases.

  March 22, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Biogen Veteran Alfred Sandrock Named CEO of Voyager Therapeutics

  Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.

  March 22, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Teva, Allergan Reach Opioid Settlement Agreement with Rhode Island

  Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.

  March 22, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Locus’ Pac-Man-Like Precision Medicine Could Negate Antibiotic Collateral Damage

  Locus Biosciences’ CRISPR-Cas3-enhanced bacteriophage (crPhage™) product attacks harmful bacteria in the microbiome while sparing human cells.

  March 22, 2022

   · 

  4 min read

   · 

  Abbey Glasure